glp-1 thyroid cancer risk More good data on for those taking meds. Retrospective data but reassuring Currently GLP1s have a warning

ZLZ PeptideRetatrutide ZLZ Peptide Retatrutide is high-scoring but not clean, with intermittent purity misses, major fill outliers (+66%, -66%), and one failed-identity/0 mg result

No exceptions

Retatrutide is not yet FDA approved, unlike many GLP-1 agonists, retatrutide will most likely be a weekly injection, delivered subcutaneously into the arm, thigh or stomach area in a self-inject pen

Retatrutide BPC-157 TB-500 FAQ What is retatrutide approved for

Why Does the Injection Site Matter

Lilly must also carry out a milk-only lactation study in lactating women who have received a dose of Foundayo to assess concentrations of orforglipron in breast milk, according to the FDA